González PN, Villafuerte TG, López CL

Language: Spanish
References: 16
Page: 237-242
PDF size: 205.30 Kb.

ABSTRACT

Introduction: Superinfection in patients with severe acute respiratory syndrome by coronavirus 2 (SARS-CoV-2) is not completely understood and requires attention to avoid the excessive use of antibiotics. Material and methods: Observational, retrospective, longitudinal, comparative study in patients with severe SARS-CoV-2 pneumonia. The accumulated probability of individual survival over 90 days was calculated with the Kaplan Meier m ethod, in groups with superinfection or absence of development of isolated microorganisms using cultures of bronchial secretion, central and peripheral blood cultures, and urine cultures. Results: Eighty-two patients were recruited, 21 (25.6%) presented bacterial or fungal growth in cultures of bronchial secretion, eight (9.7%) presented bacterial growth in peripheral blood cultures, five (6%) had bacterial development in central blood cultures, and 16 (19.5%) presented bacterial or fungal growth in urine cultures. Survival in these patients was lower, without being significant, with respect to those who did not have superinfection, (p = 0.352, 0.280, 0.119, 0.302 respectively). Conclusion: Superinfection in patients with severe SARS-CoV-2 pneumonia has not been shown to be a factor associated with lower survival, and although the prevalence of superinfection is not negligible, there is insufficient evidence to support the generalized use of empirical antibiotics.

REFERENCES

1. Esper FP, Spahlinger T, Zhou L. Rate and influence of respiratory virus coinfection on pandemic (H1N1) influenza disease. J Infect. 2011;63:260-266.

2. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: a systematic review and metaanalysis. Influenza Other Respir Viruses. 2016;10:394-403.

3. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012;40:1487-1498.

4. Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J, Mangino JE, et al. Bacterial and viral co-infections complicating severe influenza: incidence and impact among 507 US patients, 2013-14. J Clin Virol. 2016;80:12-19.

5. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest. 2011;139:555-562.

6. Huttner B, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26:808-810.

7. Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020;1(1):e11.

8. World Health Organization. Clinical management of COVID-19 interim guidance [Internet]. Geneva, Switzerland: World Health Organization; 2020. Available in: https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf?sequence=1&isAllowed=y

9. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;48:e440-e469.

10. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-481.

11. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.

12. Cao J, Hu X, Cheng W, Yu L, Tu WJ, Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med. 2020;46:851-853.

13. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71:2459-2468.

14. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622-1629. doi: 10.1016/j.cmi.2020.07.016.

15. Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community-acquired coinfection in coronavirus disease 2019: a retrospective observational experience. Clin Infect Dis. 2021;72:1450-1452. doi: 10.1093/cid/ciaa902.

16. Contou D, Claudinon A, Pajot O, Micaelo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020;10:119.